Biomarker compositions and methods of use thereof

The present disclosure provides methods and kits for identifying and treating an individual at risk of, or having, transthyretin amyloid cardiomyopathy. In general, the detection or measurement of one or more biomarkers, such as TnI, PKM1, PKM2, NT-proBNP, RBP4, DCN, TIMP2, SMOC-2, NfL, or a combination thereof, assists in the identification of transthyretin amylocardiomyopathy. The present disclosure also provides methods for selecting a patient for treatment of transthyretin amyloid cardiomyopathy, e.g., with a transthyretin stabilizer. 本公开提供了用于鉴定且治疗处于转甲状腺素蛋白淀粉样变心肌病的风险中，或患有转甲状腺素蛋白淀粉样变心肌病的个体的方法和试剂盒。一般而言，一种或多种生物标记物，例如TnI、PKM1、PKM2、NT-proBNP、RBP4、DCN、TIMP2、SMOC-2、NfL或其组合的检测或测量，帮助转甲状腺素蛋白淀粉样变心肌病的鉴定。本公开还提供了用于选择患者用于例如用转甲状腺素蛋白稳定剂治疗转甲状腺素蛋白淀粉样变心肌病的方法。